Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Ward

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
JACC. Heart Failure|April 4, 2016
Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital DatabasePaul J Hauptman, Steven W Blume, Eldrin F Lewis, et al.
Chest|July 13, 2002
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumoniaManuel Iregui, Suzanne Ward, Glenda Sherman, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 15, 2023
Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation AnalysisJaya Kala, Rebecca Nelson, Christopher Drudge, et al.
European Journal of Hospital Pharmacy : Science and Practice|October 21, 2022
Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry studyEmma Thomas, Sam Tomlinson, Siwan Thomas, et al.
Cancers|December 17, 2024
Long-Term Outcomes of 5-Fluorouracil-Related Early-Onset Toxicities: A Retrospective Cohort StudyNicolás Tentoni, Ryan Combs, Miriam Hwang, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 26, 2019
Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective studyBerna Demiralp, Lane Koenig, Jaya Kala, et al.
Pediatric Blood & Cancer|October 5, 2023
Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsKatherine A Janeway, Luis Gros, Stefan Schwartz, et al.
Pediatric Blood & Cancer|June 27, 2023
A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsKatherine A Janeway, Luis Gros, Stefan Schwartz, et al.
Clinical Drug Investigation|February 22, 2025
Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe ToxicityJorge J Garcia, Alice Beers, Paige Reid, et al.
American Journal of Perinatology|March 17, 2010
Digoxin immune fab treatment for severe preeclampsiaC David Adair, Vardaman M Buckalew, Steven W Graves, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
JACC. Heart Failure|April 4, 2016
Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital DatabasePaul J Hauptman, Steven W Blume, Eldrin F Lewis, et al.
Chest|July 13, 2002
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumoniaManuel Iregui, Suzanne Ward, Glenda Sherman, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 15, 2023
Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation AnalysisJaya Kala, Rebecca Nelson, Christopher Drudge, et al.
European Journal of Hospital Pharmacy : Science and Practice|October 21, 2022
Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry studyEmma Thomas, Sam Tomlinson, Siwan Thomas, et al.
Cancers|December 17, 2024
Long-Term Outcomes of 5-Fluorouracil-Related Early-Onset Toxicities: A Retrospective Cohort StudyNicolás Tentoni, Ryan Combs, Miriam Hwang, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 26, 2019
Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective studyBerna Demiralp, Lane Koenig, Jaya Kala, et al.
Pediatric Blood & Cancer|October 5, 2023
Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsKatherine A Janeway, Luis Gros, Stefan Schwartz, et al.
Pediatric Blood & Cancer|June 27, 2023
A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trialsKatherine A Janeway, Luis Gros, Stefan Schwartz, et al.
Clinical Drug Investigation|February 22, 2025
Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe ToxicityJorge J Garcia, Alice Beers, Paige Reid, et al.
American Journal of Perinatology|March 17, 2010
Digoxin immune fab treatment for severe preeclampsiaC David Adair, Vardaman M Buckalew, Steven W Graves, et al.
Pageof 2